Over-The-Counter (OTC) Veterinary Drugs Market size is estimated to cross US$ 18.14 Billion by 2032 | FMI

 Over-The-Counter (OTC) Veterinary Drug sales are expected to grow at an 8.1% CAGR from 2022 to 2032, reaching US$ 18.14 billion by the end of 2032. In 2021, online pharmacies held more than 38% of the total market share.

There are variety of drugs available in the market as Over-The-Counter (OTC) veterinary drugs for the safe use in animals. These drugs are available in various forms, topical drugs are available as gels, oils, creams, and sprays for various applications. Antibiotics and non-steroidal anti-inflammatory drugs are very common Over-The-Counter (OTC) veterinary drugs in the market. The drugs are available for various medical conditions related with the skin, eyes, and allergic reactions to the animals.

To learn more about this report @ https://www.futuremarketinsights.com/reports/over-the-counter-otc-veterinary-drugs-market

The Over-The-Counter (OTC) veterinary drugs market is well equipped with the retail pharmacies by the end user segment. Injectable drug involve vaccines, which are majorly used by the companion animals for their safety and improving their well-being. The Over-The-Counter (OTC) veterinary drugs market is expected to propel during the forecast period with the growing awareness on the safety and prevention of diseases among companion animals.



Over-The-Counter (OTC) Veterinary Drugs, also termed as non-prescription drugs are drugs that are available without any prescription. These drugs are effective and safe when all the directions on the label or directed by the healthcare professional are followed. The FDA in the U.S. considers when a specific drug is effective and safe enough to be sold over-the-counter. Over-the-counter (OTC) veterinary drugs usage is attributable to the savings on cost incurred on clinical visit and on the drug cost. There are limited veterinary drugs that are approved and available to veterinarians.

The veterinarians often depend on the use of different sources and types of drugs to treat their patients. Over-The-Counter (OTC) veterinary drugs are checked on the assurance of the product effectiveness, safety, and manufacturing to stringent standards for purity, quality, and potency. The FDA Centre for Veterinary Medicine (CVM) is responsible for the manufacturing and distribution of veterinary food additives and drugs. Over-The-Counter (OTC) veterinary drugs are regulated under The Federal Food, Cosmetic, and Drug ACT, which regulated statutory provisions that govern all the key regulations of Over-The-Counter (OTC) veterinary drugs.

The Act formulates drugs as, “articles for use in the cure, diagnosis, treatment, mitigation, or prevention of diseases in animals or man”.

Over-The-Counter (OTC) Veterinary Drugs Market: Drivers and Restraints-

Over-The-Counter (OTC) Veterinary Drugs are poised to witness a significant growth owing it to the paradigm shift from Rx to OTC by major pharmaceutical manufacturers. Increasing tendency of people towards the health of their companion animals in developed regions, majorly, and immense cost savings with Over-The-Counter (OTC) veterinary drugs pose various advantages, further boosting demand for Over-The-Counter (OTC) veterinary drugs.

However, several serious issues with OTC drugs pertaining to inappropriate substance abuse vehemently and diagnosis of the animal might obstruct market growth for Over-The-Counter (OTC) veterinary drugs during the forecast timeframe. This has also resulted in withdrawal of various Over-The-Counter (OTC) veterinary drugs used for therapy from the market over the years. Stringent regulations regarding Over-The-Counter (OTC) veterinary drugs and substance abuse related issues might also hinder market growth for Over-The-Counter (OTC) veterinary drugs during the forecast period.

Over-The-Counter (OTC) Veterinary Drugs Market: Region-wise Outlook

Over-The-Counter (OTC) veterinary drugs market is immensely concentrated in major developed economies like the U.S., Japan, and China. The United States is expected to witness a moderate growth due to market saturation in a few product categories. Technological advancements is however, expected to boost market growth for Over-The-Counter (OTC) veterinary drugs worldwide.

Increase in consumer appetite for Over-The-Counter (OTC) veterinary drugs for their companion animals, and growing need of curbing the veterinary-related healthcare costs is expected to fuel the market growth for Over-The-Counter (OTC) veterinary drugs in the Europe region. Increase in efforts for Over-The-Counter (OTC) veterinary drugs licensing for treatment of various diseases in animals is also expected to boost the market growth for Over-The-Counter (OTC) veterinary drugs during the forecast period. However, traditional medications for veterinary disease treatment might slow down the market growth for Over-The-Counter (OTC) veterinary drugs in the Asia-Pacific and MEA region.

Over-The-Counter (OTC) Veterinary Drugs Market: Key Market Participants

Some of the market participants in the Global Non-prescription medication identified across the value chain include: Merck & Co., Inc., Zoetis, Inc., Eli Lilly and Company, Virbac, Bayer AG, Sanofi, Vetoquinol S.A., Boehringer Ingelheim International GmbH, and Dechra Pharmaceuticals PLC.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

Key Market Segments Covered in Over-The-Counter (OTC) Veterinary Drugs Industry Research

By Drug Class :

  • NSAIDs
  • Antihistamines
  • Decongestants & Bronchodilators
  • Antibacterial
  • H2 Receptor Antagonists
  • Nutrients & Supplements
  • Glucocorticoids
  • Lubricant eye drops & artificial tears
  • Anti-parasitic
  • Antidiarrheal agents
  • Others

By Product Form :

  • Oral
  • Injectable
  • Topical
  • Others

By Sales Channel :

  • Veterinary Hospitals
  • Veterinary Clinics
  • Retail Pharmacies
  • Hypermarkets & Supermarkets
  • Online Pharmacies
  • Veterinary Shops

Comments

Post a Comment

Popular posts from this blog

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer re...
Read more